glp-1 summit 3rd GLP-1-Based Therapeutics 2026 [04/14/26] 3rd GLP-1 Based Therapeutics Summit

Anazco and Acosta [147] argue that the expanding range of pharmacological options will push the field toward personalized treatment matchingselecting interventions based on both biological and psychological patient profiles rather than on general efficacy alone

The phase 2a liver-specific trial showed: 1 mg dose: 42.9% reduction in liver fat 4 mg dose: 57.0% reduction in liver fat 8 mg dose: 81.4% reduction in liver fat 12 mg dose: 82.4% reduction in liver fat An 82% reduction in liver fat is extraordinary

This is why sulfur burps tend to be worse on GLP-1 medications than in general life

however, the risk of congenital anomalies following such exposure is not known